Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease

Debomoy Lahiri, Martin Farlow, N. Hintz, T. Utsuki, N. H. Greig

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

The extracellular deposition of amyloid beta-peptide (Aβ) in the form of cerebrovascular amyloid and extracellular plaques is one of the major neuropathological manifestations of Alzheimer's disease (AD). Aβ is generated proteolytically from the large beta-amyloid precursor protein (APP). APP is cleaved by a group of proteases called "secretase" to generate soluble derivatives of APP (sAPP), which are secreted in human plasma, CSF and cultured cells. Neurochemically, there is a severe loss of cholinergic neurons and a decreased synthesis of acetylcholine in neocortex in AD. Current approved AD drugs, such as aricept and tacrine, are based on the use of cholinesterase inhibitors (ChEIs) and have been reported to improve memory deficits and cognitive decline in some patients with AD. To compare the effects of ChEIs on APP processing, we have tested a series of ChEIs such as tacrine, physostigmine, metrifonate, phenserine and cymserine in cultured human neuroblastoma cells. We analyzed levels of sAPP by immunochemical techniques with APP-specific antibodies and assayed levels of Aβ by a sensitive sandwich ELISA. Based on these results, ChEIs can be divided into three groups: the first group of ChEIs had no effect on sAPP secretion, the second decreased the sAPP secretion only, and third group affected the secretion of sAPP and Aβ. The difference in the action of metrifonate, physostigmine, phenserine and tacrine on APP processing is independent of their selectivity for the cholinesterase enzymes. This possibly is due to the different targets that are used by ChEIs. Studying the effects of ChEIs on different targets is useful to maximize the benefit of ChEIs for the treatment of AD subjects.

Original languageEnglish
Pages (from-to)60-67
Number of pages8
JournalActa Neurologica Scandinavica, Supplement
Volume102
Issue number176
StatePublished - 2000

Fingerprint

Amyloid beta-Protein Precursor
Cholinesterase Inhibitors
Amyloid
Alzheimer Disease
Peptides
Tacrine
Trichlorfon
Physostigmine
Amyloid Precursor Protein Secretases
Cholinergic Neurons
Amyloid beta-Peptides
Neocortex
Cholinesterases
Amyloid Plaques
Memory Disorders
Plasma Cells
Neuroblastoma
Acetylcholine
Cultured Cells
Peptide Hydrolases

Keywords

  • Alzheimer's disease
  • Anticholinesterase
  • Beta-amyloid precursor protein
  • Beta-peptide
  • Butyrylch olinesterase
  • Cholinergic
  • Cholinomimetics
  • Neuroblastoma cells

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease. / Lahiri, Debomoy; Farlow, Martin; Hintz, N.; Utsuki, T.; Greig, N. H.

In: Acta Neurologica Scandinavica, Supplement, Vol. 102, No. 176, 2000, p. 60-67.

Research output: Contribution to journalArticle

@article{ba784d3371364b84ae9f6626227c425b,
title = "Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease",
abstract = "The extracellular deposition of amyloid beta-peptide (Aβ) in the form of cerebrovascular amyloid and extracellular plaques is one of the major neuropathological manifestations of Alzheimer's disease (AD). Aβ is generated proteolytically from the large beta-amyloid precursor protein (APP). APP is cleaved by a group of proteases called {"}secretase{"} to generate soluble derivatives of APP (sAPP), which are secreted in human plasma, CSF and cultured cells. Neurochemically, there is a severe loss of cholinergic neurons and a decreased synthesis of acetylcholine in neocortex in AD. Current approved AD drugs, such as aricept and tacrine, are based on the use of cholinesterase inhibitors (ChEIs) and have been reported to improve memory deficits and cognitive decline in some patients with AD. To compare the effects of ChEIs on APP processing, we have tested a series of ChEIs such as tacrine, physostigmine, metrifonate, phenserine and cymserine in cultured human neuroblastoma cells. We analyzed levels of sAPP by immunochemical techniques with APP-specific antibodies and assayed levels of Aβ by a sensitive sandwich ELISA. Based on these results, ChEIs can be divided into three groups: the first group of ChEIs had no effect on sAPP secretion, the second decreased the sAPP secretion only, and third group affected the secretion of sAPP and Aβ. The difference in the action of metrifonate, physostigmine, phenserine and tacrine on APP processing is independent of their selectivity for the cholinesterase enzymes. This possibly is due to the different targets that are used by ChEIs. Studying the effects of ChEIs on different targets is useful to maximize the benefit of ChEIs for the treatment of AD subjects.",
keywords = "Alzheimer's disease, Anticholinesterase, Beta-amyloid precursor protein, Beta-peptide, Butyrylch olinesterase, Cholinergic, Cholinomimetics, Neuroblastoma cells",
author = "Debomoy Lahiri and Martin Farlow and N. Hintz and T. Utsuki and Greig, {N. H.}",
year = "2000",
language = "English",
volume = "102",
pages = "60--67",
journal = "Acta psychiatrica et neurologica. Supplementum",
issn = "0065-1427",
publisher = "Wiley-Blackwell",
number = "176",

}

TY - JOUR

T1 - Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease

AU - Lahiri, Debomoy

AU - Farlow, Martin

AU - Hintz, N.

AU - Utsuki, T.

AU - Greig, N. H.

PY - 2000

Y1 - 2000

N2 - The extracellular deposition of amyloid beta-peptide (Aβ) in the form of cerebrovascular amyloid and extracellular plaques is one of the major neuropathological manifestations of Alzheimer's disease (AD). Aβ is generated proteolytically from the large beta-amyloid precursor protein (APP). APP is cleaved by a group of proteases called "secretase" to generate soluble derivatives of APP (sAPP), which are secreted in human plasma, CSF and cultured cells. Neurochemically, there is a severe loss of cholinergic neurons and a decreased synthesis of acetylcholine in neocortex in AD. Current approved AD drugs, such as aricept and tacrine, are based on the use of cholinesterase inhibitors (ChEIs) and have been reported to improve memory deficits and cognitive decline in some patients with AD. To compare the effects of ChEIs on APP processing, we have tested a series of ChEIs such as tacrine, physostigmine, metrifonate, phenserine and cymserine in cultured human neuroblastoma cells. We analyzed levels of sAPP by immunochemical techniques with APP-specific antibodies and assayed levels of Aβ by a sensitive sandwich ELISA. Based on these results, ChEIs can be divided into three groups: the first group of ChEIs had no effect on sAPP secretion, the second decreased the sAPP secretion only, and third group affected the secretion of sAPP and Aβ. The difference in the action of metrifonate, physostigmine, phenserine and tacrine on APP processing is independent of their selectivity for the cholinesterase enzymes. This possibly is due to the different targets that are used by ChEIs. Studying the effects of ChEIs on different targets is useful to maximize the benefit of ChEIs for the treatment of AD subjects.

AB - The extracellular deposition of amyloid beta-peptide (Aβ) in the form of cerebrovascular amyloid and extracellular plaques is one of the major neuropathological manifestations of Alzheimer's disease (AD). Aβ is generated proteolytically from the large beta-amyloid precursor protein (APP). APP is cleaved by a group of proteases called "secretase" to generate soluble derivatives of APP (sAPP), which are secreted in human plasma, CSF and cultured cells. Neurochemically, there is a severe loss of cholinergic neurons and a decreased synthesis of acetylcholine in neocortex in AD. Current approved AD drugs, such as aricept and tacrine, are based on the use of cholinesterase inhibitors (ChEIs) and have been reported to improve memory deficits and cognitive decline in some patients with AD. To compare the effects of ChEIs on APP processing, we have tested a series of ChEIs such as tacrine, physostigmine, metrifonate, phenserine and cymserine in cultured human neuroblastoma cells. We analyzed levels of sAPP by immunochemical techniques with APP-specific antibodies and assayed levels of Aβ by a sensitive sandwich ELISA. Based on these results, ChEIs can be divided into three groups: the first group of ChEIs had no effect on sAPP secretion, the second decreased the sAPP secretion only, and third group affected the secretion of sAPP and Aβ. The difference in the action of metrifonate, physostigmine, phenserine and tacrine on APP processing is independent of their selectivity for the cholinesterase enzymes. This possibly is due to the different targets that are used by ChEIs. Studying the effects of ChEIs on different targets is useful to maximize the benefit of ChEIs for the treatment of AD subjects.

KW - Alzheimer's disease

KW - Anticholinesterase

KW - Beta-amyloid precursor protein

KW - Beta-peptide

KW - Butyrylch olinesterase

KW - Cholinergic

KW - Cholinomimetics

KW - Neuroblastoma cells

UR - http://www.scopus.com/inward/record.url?scp=0034489269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034489269&partnerID=8YFLogxK

M3 - Article

VL - 102

SP - 60

EP - 67

JO - Acta psychiatrica et neurologica. Supplementum

JF - Acta psychiatrica et neurologica. Supplementum

SN - 0065-1427

IS - 176

ER -